Literature DB >> 17461856

CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997-2003.

W Stöhr1, Dt Dunn, K Porter, T Hill, B Gazzard, J Walsh, R Gilson, P Easterbrook, M Fisher, Ma Johnson, Vc Delpech, An Phillips, Ca Sabin.   

Abstract

OBJECTIVES: We examined whether the timing of initiation of antiretroviral therapy (ART) in routine clinical practice reflected treatment guidelines, which have evolved towards recommending starting therapy at lower CD4 cell counts.
METHODS: We analysed longitudinal data on 10,820 patients enrolled in the UK Collaborative HIV Cohort (UK CHIC) Study, which includes seven large clinical centres in south-east England. CD4 cell and viral load measurements performed in the period between 1 January 1997 and 31 December 2003 were classified according to whether ART was subsequently initiated or deferred, to estimate the probability of ART initiation by CD4 count and viral load over time. The effect of nonclinical factors (age, sex, ethnicity, and exposure category) was analysed by logistic regression. Kaplan-Meier analysis was used to estimate the proportion of patients who had initiated ART by a particular CD4 count among 'early' presenters (initial CD4 cell count >500 cells/microL).
RESULTS: There was a tendency to initiate ART at lower CD4 cell counts over time in the years 1997-2000, especially in the range 200-500 cells/microL, with little change thereafter. An estimated 34% of HIV-infected individuals having presented early initiated ART at a CD4 count <200 cells/microL. We also found an independent influence of viral load, which was particularly pronounced for CD4 <350 cells/microL. Use of injection drugs was the only nonclinical factor associated with initiation of ART at lower CD4 cell counts.
CONCLUSIONS: The initiation of ART in the clinics included in this analysis reflected evolving treatment guidelines. However, an unexpectedly high proportion of patients started ART at lower CD4 counts than recommended, which is only partly explained by late presentation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461856     DOI: 10.1111/j.1468-1293.2007.00443.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  9 in total

1.  Accounting for data errors discovered from an audit in multiple linear regression.

Authors:  Bryan E Shepherd; Chang Yu
Journal:  Biometrics       Date:  2011-01-31       Impact factor: 2.571

2.  Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.

Authors:  A Plettenberg; N H Brockmeyer; B Haastert; C Michalik; S Dupke; K Schewe; M Rausch; M Hower; A Ulmer; E Wolf; T Lorenzen; G Arendt; K Jansen
Journal:  Infection       Date:  2011-01-11       Impact factor: 3.553

3.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

4.  Assessing the predictive value of HIV indicator conditions in general practice: a case-control study using the THIN database.

Authors:  Sarah Damery; Linda Nichols; Roger Holder; Ronan Ryan; Sue Wilson; Sally Warmington; Helen Stokes-Lampard; Kaveh Manavi
Journal:  Br J Gen Pract       Date:  2013-06       Impact factor: 5.386

5.  Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.

Authors:  Margaret May; Mark Gompels; Valerie Delpech; Kholoud Porter; Frank Post; Margaret Johnson; David Dunn; Adrian Palfreeman; Richard Gilson; Brian Gazzard; Teresa Hill; John Walsh; Martin Fisher; Chloe Orkin; Jonathan Ainsworth; Loveleen Bansi; Andrew Phillips; Clifford Leen; Mark Nelson; Jane Anderson; Caroline Sabin
Journal:  BMJ       Date:  2011-10-11

6.  HIV testing in non-traditional settings--the HINTS study: a multi-centre observational study of feasibility and acceptability.

Authors:  Michael Rayment; Alicia Thornton; Sundhiya Mandalia; Gillian Elam; Mark Atkins; Rachael Jones; Anthony Nardone; Patrick Roberts; Melinda Tenant-Flowers; Jane Anderson; Ann K Sullivan
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

7.  Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).

Authors:  Guido Schäfer; Christian Hoffmann; Keikawus Arasteh; Dirk Schürmann; Christoph Stephan; Björn Jensen; Matthias Stoll; Johannes R Bogner; Gerd Faetkenheuer; Jürgen Rockstroh; Hartwig Klinker; Georg Härter; Albrecht Stöhr; Olaf Degen; Eric Freiwald; Anja Hüfner; Sabine Jordan; Julian Schulze Zur Wiesch; Marylyn Addo; Ansgar W Lohse; Jan van Lunzen; Stefan Schmiedel
Journal:  AIDS Res Ther       Date:  2019-11-15       Impact factor: 2.250

8.  Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom.

Authors:  Gareth J Hughes; Esther Fearnhill; David Dunn; Samantha J Lycett; Andrew Rambaut; Andrew J Leigh Brown
Journal:  PLoS Pathog       Date:  2009-09-25       Impact factor: 6.823

9.  Older HIV-infected individuals present late and have a higher mortality: Brighton, UK cohort study.

Authors:  Collins C Iwuji; Duncan Churchill; Yvonne Gilleece; Helen A Weiss; Martin Fisher
Journal:  BMC Public Health       Date:  2013-04-26       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.